Calumet stock
CLMTNASDAQCalumet Inc., Basic MaterialsISIN US1314281049
47Score 47 out of 100, Weak
Price and trend
44 / 100
Price history
+93% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.5% below it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 24).
The price is 38% below its 52-week high. Largest decline in 20 years: 98% (April 2007 to March 2020).
Chart figures for advanced users
- SMA 50$52.24
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$39.40
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)24
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.22
- The lowest closing price of the last twelve months.
- Resistance$59.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Calumet Inc. belongs to the Chemicals (Specialty) industry (United States) and, with a market value of $3.2B, is number 77 of 108 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.14B (down 1.2% year on year) and a loss of $33.8M.
- For fiscal 2026, analysts expect on average revenue of $5.09B (up 23%) and adjusted earnings per share of −$2.07.
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 351 of 467 in Basic Materials, median 58.
- Our model puts fair value at $42.20, with the price 15% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 12.8% a year since 2020, Chemicals (Specialty) median 6%.Growth 77
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.4 times.Stability 29
- Loss-makingLoss of $193.8M over the last 12 months.Fundamentals 30
- DilutionShare count up 11% since 2020.Capital allocation 43
Its standout strengths are growth and momentum, while stability and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 46 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $30.14 and expensive above $70.33 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $35.27, at 8.4% it would be $52.18.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 28.4% on the twelve months before. Revenue has grown solidly since 2006, at about 5% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 6%, operating 1%, net −1%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 26 Feb 2027in 106 days
- Last reported
- 6 Nov 2026EPS reported $2.91 (expected $1.63)above expectations
Analyst estimates
- Earnings per share
- −$2.07+9.1%
- Revenue
- $5.09B+3.1%
- Earnings per share
- $2.68+23.7%
- Revenue
- $4.94B+5.3%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +8.6%No numerical guidance; continued and accelerated deleveraging is expected and the outlook is described as constructive, with no change versus earlier.
“The outlook is for continued and accelerated deleveraging from here.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 2 insiders sold, $20.55M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Calumet
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 47
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals (Specialty)
The next larger and next smaller companies by market value
- AshlandASH $3.51B53
- HEXPOLHPOL-B.ST $3.31B68
- Azelis GroupAZE.BR $3.18B59
- HawkinsHWKN $3.16B69
- WD-40WDFC $2.94B73
- H.B. FullerFUL $2.73B53
- Quaker HoughtonKWR $2.68B54
- IngevityNGVT $2.14B60
ETFs that hold Calumet
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.09% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.08% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.08% | 0.30% | €4.22B |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.03% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Nov 2013)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.